MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Relmada Therapeutics ROCE Ratio 2011-2026 | RLMD
Annual ROCE Ratio Relmada Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -68.31 | -236.17 | -121.49 | -114.82 | -60.36 | -57.62 | -167.18 | 242.16 | -494.34 | -225.74 | -194.09 | 1283.5 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1283.5 | -494.34 | -17.87 |
Quarterly ROCE Ratio Relmada Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -263.27 | -302.69 | -224.19 | -192.01 | -110.82 | -133.35 | -108.42 | -100.25 | -68.34 | -91.63 | -92.22 | -87.05 | -64.61 | -123.29 | -127.33 | -128.79 | -110.58 | -126.86 | -80.26 | -62.39 | -37.8 | -41.01 | -28.31 | -19.43 | -9.99 | -252.48 | -417.34 | -824.32 | -793.53 | -753.02 | -651.92 | -443.34 | -537.89 | -368.78 | -330.81 | -150.65 | -106.64 | -122.42 | -126.87 | -170.01 | -199.6 | -246.44 | -195.01 | 265.34 | 653.58 | 777.21 | 4287.39 | 3983.49 | 3699.09 | 3671.17 | 112.89 | -0.46 | 0.24 | -30.14 | -21.84 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4287.39 | -824.32 | 144.95 |
ROCE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
7.34 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-73.94 | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-5.51 | $ 5.66 | 0.98 % | $ 84.1 M | USA |
 |
HEXO Corp.
HEXO
|
-340.37 | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-33.39 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-79.15 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-207.12 | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
3101.1 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
267.43 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
121.85 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-4.18 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-1.59 | $ 2.72 | 1.49 % | $ 1.04 B | Canada |
 |
Athenex
ATNX
|
1076.15 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
58.18 | $ 38.34 | 1.86 % | $ 1.41 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-57.41 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-20.78 | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
34.66 | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
-24.04 | $ 1.03 | 3.01 % | $ 111 M | Canada |
 |
Organogenesis Holdings
ORGO
|
14.89 | $ 2.42 | 3.21 % | $ 307 M | USA |
 |
Pacira BioSciences
PCRX
|
-9.43 | $ 23.0 | 0.04 % | $ 1.06 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-84.11 | $ 1.12 | 2.75 % | $ 1.39 M | USA |
 |
Aurora Cannabis
ACB
|
0.81 | $ 3.17 | 4.11 % | $ 174 M | Canada |
 |
Solid Biosciences
SLDB
|
-90.02 | $ 7.3 | 2.17 % | $ 639 M | USA |
 |
Jupiter Wellness
JUPW
|
-116.71 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
70.21 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-11.66 | $ 1.07 | 0.47 % | $ 102 M | Canada |
 |
Tilray
TLRY
|
-41.31 | $ 5.14 | 3.21 % | $ 3.18 B | Canada |
 |
cbdMD
YCBD
|
-29.93 | $ 0.71 | 3.49 % | $ 2.86 M | USA |
 |
Evolus
EOLS
|
141.36 | $ 6.68 | -0.74 % | $ 431 M | USA |
 |
Sundial Growers
SNDL
|
-68.48 | $ 1.46 | 2.46 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
19.15 | $ 8.41 | 1.08 % | $ 450 M | USA |
 |
Veru
VERU
|
-135.01 | $ 3.05 | 1.61 % | $ 44.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-39.01 | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
-22.92 | $ 23.49 | 0.02 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
-265.79 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
21.53 | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
-327.26 | $ 5.13 | 1.38 % | $ 1.9 B | Canada |
 |
PetIQ
PETQ
|
5.46 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
-6.09 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
40.43 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-32.55 | $ 4.25 | 0.47 % | $ 212 M | USA |
 |
PLx Pharma
PLXP
|
-114.37 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
-18.1 | $ 16.43 | -0.27 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
-73.1 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-76.25 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-12.68 | $ 0.64 | 2.32 % | $ 23 M | USA |
 |
Tricida
TCDA
|
-70162.39 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-14.24 | $ 0.77 | 7.74 % | $ 3.3 M |  China |
 |
TherapeuticsMD
TXMD
|
-16.33 | $ 2.29 | 4.09 % | $ 26.5 M | USA |